Ascendis Pharma A (ASND) Equity Income (2019 - 2026)
Ascendis Pharma A (ASND) reported Equity Income of -$12.0 million for Q1 2026, down 142.93% on a YoY basis from $28.0 million in Q1 2025, and down 876.36% sequentially from $1.5 million in Q4 2025.
Ascendis Pharma A (ASND) Equity Income (2019 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 8 years of Equity Income data on file, last reported at -$12.0 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Income fell 142.93% year-over-year to -$12.0 million; the trailing twelve-month figure through Mar 2026 stood at -$23.9 million (down 290.26% YoY), and the FY2025 full-year result was $19.0 million, up 187.43% from the prior year.
- Equity Income slipped to -$12.0 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of $28.0 million in Q1 2025 to a low of -$12.0 million in Q1 2026.
- A 5-year average of -$3.3 million and a median of -$4.9 million in 2024 frame the typical range for Equity Income.
- Across the five-year window, Equity Income tumbled 552.12% in 2023 and soared 544.02% in 2025, its largest moves.
- Tracing ASND's Equity Income over 5 years: stood at -$8.1 million in 2022, then soared by 61.27% to -$3.1 million in 2023, then tumbled by 55.4% to -$4.9 million in 2024, then jumped by 131.62% to $1.5 million in 2025, then slumped by 876.36% to -$12.0 million in 2026.
- Business Quant data shows ASND's Equity Income at -$12.0 million in Q1 2026, $1.5 million in Q4 2025, and -$8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ascendis Pharma A | 15.31 Bn | 14.64 Bn | 268.20 Mn | -12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.00 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | -8.77 Mn |
| Jun 30, 2025 | -4.64 Mn |
| Mar 31, 2025 | 27.96 Mn |
| Dec 31, 2024 | -4.89 Mn |
| Sep 30, 2024 | -4.80 Mn |
| Jun 30, 2024 | -5.73 Mn |
| Mar 31, 2024 | -6.30 Mn |
| Dec 31, 2023 | -3.15 Mn |
| Sep 30, 2023 | -7.40 Mn |
| Jun 30, 2023 | -8.11 Mn |
| Mar 31, 2023 | -1.32 Mn |
| Dec 31, 2022 | -8.12 Mn |
| Sep 30, 2022 | -3.73 Mn |
| Jun 30, 2022 | -1.24 Mn |
| Mar 31, 2022 | -5.47 Mn |
| Dec 31, 2021 | 36.01 Mn |
| Sep 30, 2021 | -4.55 Mn |
| Jun 30, 2021 | -5.80 Mn |